Needham & Company LLC Reiterates Hold Rating for STERIS (NYSE:STE)

STERIS (NYSE:STE)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a research report issued on Monday,Benzinga reports.

Other analysts also recently issued reports about the stock. Piper Sandler upped their price objective on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research report on Thursday, February 6th. Finally, Stephens reissued an “overweight” rating and set a $240.00 price objective on shares of STERIS in a research report on Thursday, February 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $258.75.

STERIS Stock Up 0.3 %

Shares of STE traded up $0.55 during midday trading on Monday, reaching $213.16. 369,848 shares of the stock were exchanged, compared to its average volume of 532,622. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. The company has a market cap of $20.94 billion, a price-to-earnings ratio of 45.16 and a beta of 0.87. STERIS has a 12-month low of $197.82 and a 12-month high of $248.24. The firm has a 50 day simple moving average of $223.23 and a 200-day simple moving average of $220.44.

STERIS (NYSE:STE) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. Research analysts forecast that STERIS will post 9.08 EPS for the current year.

Institutional Trading of STERIS

A number of institutional investors and hedge funds have recently modified their holdings of STE. Magnolia Capital Advisors LLC boosted its stake in STERIS by 1.9% during the fourth quarter. Magnolia Capital Advisors LLC now owns 2,534 shares of the medical equipment provider’s stock worth $521,000 after buying an additional 48 shares in the last quarter. SkyView Investment Advisors LLC boosted its position in shares of STERIS by 1.6% during the 3rd quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock valued at $765,000 after acquiring an additional 51 shares in the last quarter. Park Edge Advisors LLC raised its position in STERIS by 1.1% in the fourth quarter. Park Edge Advisors LLC now owns 4,662 shares of the medical equipment provider’s stock worth $958,000 after purchasing an additional 51 shares in the last quarter. Citizens Financial Group Inc. RI lifted its stake in STERIS by 5.9% during the fourth quarter. Citizens Financial Group Inc. RI now owns 975 shares of the medical equipment provider’s stock worth $201,000 after purchasing an additional 54 shares during the period. Finally, Opal Wealth Advisors LLC boosted its holdings in STERIS by 5.7% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,118 shares of the medical equipment provider’s stock valued at $230,000 after purchasing an additional 60 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.